Transmedics Group Inc (TMDX)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

200 MINUTEMAN ROAD ANDOVER, MA 01810

TransMedics Group, Inc. is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company developed the Organ Care System, or the OCS, to replace a decades-old standard of care that they believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide.

Data as of 2021-01-16
Market Cap509.537 Million Shares Outstanding27.161 Million Avg 30-day Volume93.947 Thousand
P/E Ratio-15.2 Dividend Yield EPS-1.28
Price/Sales28.289 Price cash flow ratio Price free cash flow ratio-22.4
Book Value4.03 Price to Tangible Book4.82 Alpha-0.03
Short Interest Ratio % Short Interest to Float R-squared0.360365
BETA2.16436 52-week High/Low20.99 / 10.1 Stddev0.218342
View SEC Filings from TMDX instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 1 -100.0% 0 (0.0%) 1 (0.06%) -100.0%
Funds Holding: 71 69 2.9% 16 (1.05%) 19 (1.23%) -15.79%
13F shares: 20.816 Million 20.159 Million 3.26% 6.95 Million 7.475 Million -7.02%
% Ownership 76.6559 74.3568 3.09% 25.5929 27.5706 -7.17%
New Positions: 14 20 -30.0% 5 8 -37.5%
Increased Positions 32 32 0.0% 5 7 -28.57%
Closed Positions 11 5 120.0% 8 2 300.0%
Reduced Positions 15 11 36.36% 3 1 200.0%
Total Calls 15 0
Total Puts 75 Thousand 0 75 Thousand
PUT/CALL Ratio 5,000.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding TMDX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TMDX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

14 Thousand total shares from 4 transactions

Exercise Derivative Conversion (M)

132 Thousand total shares from 4 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HASSANEIN WALEED H PRESIDENT & CEO

  • Officer
  • Director
338,843 2021-01-05 3

RAINES MERILEE

  • Director
0 2021-01-01 2

GORDON STEPHEN CHIEF FINANCIAL OFFICER

  • Officer
18,126 2020-12-31 4

SULLIVAN JOHN F VP OF QUALITY & ENGINEERING

  • Officer
10,828 2020-12-21 3

PROVOST MIRIAM VP OF US REGULATORY & FDA REL.

  • Officer
4,600 2020-12-11 2

CAREY JOHN F VP OF OPERATIONS

  • Officer
3,200 2020-09-01 9

TOBIN JAMES R

  • Director
0 2020-06-04 1

GUNDERSON THOMAS JAMES

  • Director
0 2020-06-04 1

WEILL DAVID

  • Director
0 2020-06-04 1

BASILE EDWARD M

  • Director
0 2020-06-04 1

KHAYAL TAMER I CHIEF COMMERCIAL OFFICER

  • Officer
0 2020-02-27 2

DAMME LAURA VP, CLINICAL AFFAIRS

  • Officer
0 2020-02-27 1

KANIA EDWIN M JR

  • Director
1,019,748 2019-12-12 0

UNITED THERAPEUTICS CORP

LUNG BIOTECHNOLOGY PBC

  • 10% Owner
2,053,240 2019-12-09 0

FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

FLAGSHIP VENTURES FUND IV, L.P.

FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC

FLAGSHIP VENTURES FUND 2007, L.P.

AFEYAN NOUBAR

  • 10% Owner
120,595 2019-10-29 0

ABRAMS CAPITAL MANAGEMENT, L.P.

ABRAMS CAPITAL MANAGEMENT, LLC

ABRAMS CAPITAL, LLC

ABRAMS DAVID C

ABRAMS CAPITAL PARTNERS II, L.P.

RIVA CAPITAL PARTNERS III, L.P.

RIVA CAPITAL MANAGEMENT III, LLC

  • 10% Owner
3,499,859 2019-05-06 0

GILBERT JAMES

  • Director
0 2019-05-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

HASSANEIN WALEED H - Director - Officer PRESIDENT & CEO

2021-01-14 18:56:13 -0500 2021-01-05 M 123,414 $0.39 a 338,843 direct

HASSANEIN WALEED H - Director - Officer PRESIDENT & CEO

2021-01-14 18:56:13 -0500 2021-01-05 M 123,414 d 0 direct

GORDON STEPHEN - Officer CHIEF FINANCIAL OFFICER

2021-01-05 18:04:42 -0500 2021-01-04 S 1,184 $20.00 d 8,371 direct yes -2.0419 -0.7726 3.532 3 -2.0419 2

RAINES MERILEE - Director

2021-01-05 17:57:41 -0500 2021-01-01 A 18,000 a 18,000 direct

GORDON STEPHEN - Officer CHIEF FINANCIAL OFFICER

2021-01-05 18:04:42 -0500 2020-12-31 S 8,816 $20.00 d 9,755 direct yes -2.0419 -0.7726 3.532 3 -2.0419 2

SULLIVAN JOHN F - Officer VP OF QUALITY & ENGINEERING

2020-12-22 16:19:19 -0500 2020-12-21 S 1,000 $17.99 d 10,828 direct yes -0.3715 5.6263 5.6263 6 -0.3715 2

SULLIVAN JOHN F - Officer VP OF QUALITY & ENGINEERING

2020-12-17 17:57:14 -0500 2020-12-16 M 1,000 $0.39 a 11,828 direct -1.9818 1.714 1.714 6 -1.9818 2

SULLIVAN JOHN F - Officer VP OF QUALITY & ENGINEERING

2020-12-17 17:57:14 -0500 2020-12-16 M 1,000 a 10,617 direct

SULLIVAN JOHN F - Officer VP OF QUALITY & ENGINEERING

2020-12-17 17:57:14 -0500 2020-12-15 M 3,000 a 11,617 direct yes

SULLIVAN JOHN F - Officer VP OF QUALITY & ENGINEERING

2020-12-17 17:57:14 -0500 2020-12-15 M 3,000 $0.39 a 13,828 direct yes -1.9818 1.714 1.714 6 -1.9818 2

SULLIVAN JOHN F - Officer VP OF QUALITY & ENGINEERING

2020-12-17 17:57:14 -0500 2020-12-15 S 3,000 $16.63 d 10,828 direct yes -1.9818 1.714 1.714 6 -1.9818 2

PROVOST MIRIAM - Officer VP OF US REGULATORY & FDA REL.

2020-12-14 16:53:15 -0500 2020-12-11 M 4,600 $3.22 a 4,600 direct -0.1676 4.7486 4.7486 6 -0.1676 2

PROVOST MIRIAM - Officer VP OF US REGULATORY & FDA REL.

2020-12-14 16:53:15 -0500 2020-12-11 M 4,600 d 23,971 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments